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Abstract
Background: The Plasmodium protein Cell-traversal protein for ookinetes and sporozoites (CelTOS) plays an important role
in cell traversal of host cells in both, mosquito and vertebrates, and is required for successful malaria infections. CelTOS is
highly conserved among the Plasmodium species, suggesting an important functional role across all species. Therefore,
targeting the immune response to this highly conserved protein and thus potentially interfering with its biological function
may result in protection against infection even by heterologous species of Plasmodium.
Methodology/Principal Findings: To test this hypothesis, we developed a recombinant codon-harmonized P. falciparum
CelTOS protein that can be produced to high yields in the E. coli expression system. Inbred Balb/c and outbred CD-1 mice
were immunized with various doses of the recombinant protein adjuvanted with Montanide ISA 720 and characterized
using in vitro and in vivo analyses.
Conclusions/Significance: Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and
most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of
both inbred and outbred mice. The biological activity of CelTOS-specific antibodies against the malaria parasite is likely
linked to the impairment of sporozoite motility and hepatocyte infectivity. The results underscore the potential of this
antigen as a pre-erythrocytic vaccine candidate and demonstrate for the first time a malaria vaccine that is cross-protective
between species.
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Introduction
Malaria remains a significant disease in most tropical countries
and despite prophylactic efforts in the form of bed nets and the
development of novel anti-malarial drugs, the disease is still a major
threat to global health and the survival of children under the age of
five. The current lead malaria vaccine, now in Phase III trials,
GlaxoSmithKline’s RTS,S vaccine, has shown a 53% reduction in
clinical episodes of malaria for eight months in children 5 to 17
months old [1]; and in a trial in Mozambique children aged 1 to 4
years, the vaccine was capable of providing protection for up to 45
months,butata lowerefficacy[2].Althoughthe resultsfrom RTS,S
vaccination are encouraging, there remains a need to increase the
observedvaccineefficacyofpre-erythrocyticvaccinecandidatesand
this may be achieved by either modifying the adjuvant partners,
changing the vaccine delivery platform or by the addition of new
antigens. These approaches have primarily focused on the
circumsporozoite protein (CSP) (reviewed in [3]) as the target
antigen and as such it is not clear whether other pre-erythrocytic
antigens can substitute for CSP or can act in combination with a
CSP-based vaccine to achieve the required increase in vaccine
efficacy. Moreover, immunity based on anti-CSP responses is
species-specific [4,5] and thus the CS proteins of the different
Plasmodium species would have to be included in a combination
vaccine approach in order to protect individuals living in areas with
mixed Plasmodium species.
Genomic and proteomic data mining have identified novel
Plasmodium antigens that are either restricted to the sporozoite and/
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antigens is the cell-traversal protein for ookinetes and sporozoites
(CelTOS) identified independently by two laboratories through
either comparative screening of genomic databases for immuno-
genic antigens [6] or using suppression subtractive hybridization
(SSH) of Plasmodium yoelii sporozoites versus merozoites [7]. Shortly
thereafter, the antigen was identified again by screening P. berghei
expressed sequence tag (EST) databases of salivary glands and
ookinetes [8]. Using P. berghei as the model, genetic disruptions of
celtos not only reduced sporozoite infectivity of the liver, but also
reduced cell passage through the liver sinusoid as well as reduced
passagethroughthemidgut epithelium by ookinetes [8].The notion
that CelTOS is an important protein for the traversal of the malaria
parasite in both, the mammalian and the insect host, warranted an
evaluation of whether targeted immune responses against this
antigen could prevent the infection of the liver in the mammalian
host. Concomitantly, others have attributed immunological signif-
icance to CelTOS by demonstrating that CelTOS-specific peptides
can stimulate the PBMC’s isolated from volunteers immunized with
irradiated sporozoites, a highly effective vaccine inducing sterile
protection, to produce antigen-specific IFN-c responses, emphasiz-
ing the potential immunological impact of this antigen [6]. This
study reported that CelTOS-specific peptides stimulate the highest
IFN-cresponsesinPBMC’s,higherthanevenusingCSPor,TRAP,
LSA1 and EXP1 or any of the other newly discovered antigens
being evaluated. CelTOS may also be an attractive target since the
protein is highly conserved [8] thus potentially requiring only a
single subunit vaccine to induce broadly protective immunity
against multiple Plasmodium species.
The objective of the present study was to evaluate the capacity
of the recombinant CelTOS protein to induce sterile protection in
mice against a heterologous challenge with P. berghei sporozoites.
First, we codon-harmonized the gene sequence of PfCelTOS for
optimal expression in E. coli based on our previously published
algorithm [9]. This resulted in high expression levels of a soluble,
full length protein. Various doses of the CelTOS protein
emulsified with Montanide ISA-720 were tested for their pro-
tective potential after three immunizations. Optimal antigen doses
consistently induced sterile protection in 50–60% of both, outbred
as well as inbred mice. Characterization of the immune response
revealed that both humoral and cellular responses may play a role
in the heterologous protection against P. berghei challenge.
Currently, the immune mechanism(s) correlating with protection
mediated by CelTOS remain to be elucidated. These results are
quite encouraging as they represent the first vaccine approach
mediating protection against a heterologous sporozoite challenge.
Results
Immunization with PfCelTOS results in sterile protection
against heterologous challenge with P. berghei
sporozoites in inbred and outbred mice
To determine whether CelTOS is a protective antigen against
heterologous challenge, Balb/c and CD-1 mice were immunized
with different doses of P. falciparum CelTOS recombinant protein
(PfCelTOS) (Purification profile Figure S1) adjuvanted with
Montanide ISA 720 and challenged subcutaneously with P. berghei
sporozoites two weeks after the last immunization. Challenge
control mice received saline adjuvanted with Montanide ISA 720.
Mice that did not develop parasitemia by day 14 were considered
to be protected (Figure 1). PfCelTOS induced protection in both,
inbred and outbred animals that was statistically significant
compared to control Montanide ISA 720 for Balb/c mice using
the 10 mg dose (p=0.01 Fisher’s exact T-test) and for CD-1 mice
using both the 25 mg dose (p=0.01) and the 10 mg dose (p=
0.001). However, the optimal dose was 10 mg protein/immuniza-
tion emulsified with Montanide ISA 720 for both strains of mice
achieving sterile protection in approximately 60% of the mice.
Interestingly, the dose response in CD-1 mice was not linear, with
the higher dose tested, 25 mg, resulting in reduced efficacy
compared with the 10 mg dose.
Immunization with PfCelTOS adjuvanted in Montanide
ISA 720 results in high antibody titers
To evaluate the immunogenicity of PfCelTOS, inbred Balb/c
and outbred CD-1 mice were immunized three times with various
doses of recombinant PfCelTOS emulsified in Montanide ISA
720. Sera were collected two days prior to each immunization
(post 1, post 2) or 2 days prior to challenge (post 3) and tested in a
quantitative ELISA (Figure 2). The antibody response in both
strains reached a saturation plateau after the second immunization
when immunized with the highest vaccine dose tested. As the
mechanism of protective immunity by this vaccine is not known,
we stratified the pre-challenge antibody-data by protective status
of the animals (Figure 3). While there was a trend towards higher
medians in some of the protected animals, there was no statistical
difference between mice that later became infected versus the mice
that were protected after challenge.
CelTOS-specific monoclonal and polyclonal antibodies
react with sporozoites
We next sought to determine whether antibodies induced by
recombinant protein immunization could recognize native antigen
Figure 1. Immunization with recombinant PfCelTOS induces
sterile protection against a heterologous sporozoite challenge
with P. berghei. Inbred Balb/c mice and outbred CD-1 mice were
immunized three times with the indicated doses and challenged two
weeks after the last immunizations by subcutaneous injection of either
4,000 (for Balb/c) or 15,000 (for CD-1 mice) sporozoites. Vaccine efficacy
was calculated using the formula: Efficacy = [1-[(number of infected
animals (I)vaccine/total number of animals (n)vaccine)4(number of
infected animals control (I)/total number of animals (n) control)]]*100.
The numbers above bars represent the number of protected animals/
total number of animals in the group. Statistical significance was
determined with Fisher Exact test (two-tailed) and is indicated by
asterisks (* p=0.01, ** p=0.001).
doi:10.1371/journal.pone.0012294.g001
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Immunostaining using polyclonal anti-PfCelTOS antisera from
Balb/c mice immunized with PfCelTOS/ISA 720 (post-3 sera)
showed reactivity with homologous P. falciparum (Panel A) as well
as with the heterologous P. berghei sporozoites (Panel B). Positive
control staining of P. falciparum sporozoites (Panel C) and P. berghei
sporozoites (Panel D) was performed using PfCelTOS-specific
mAb 2C7 or PbCelTOS-specific mAb 15E2, respectively (pro-
duced in our laboratory). Sera from mice that had only received
the adjuvant, as well as pre-immune sera, did not react with the
sporozoites (data not shown).
CelTOS-specific antibodies inhibit invasion of
hepatocytes by P. falciparum sporozoites in vitro
Gene knockout experiments suggest that CelTOS may be an
advantageous immunological target against hepatocyte infectivity
(8). Thus we designed experiments to determine whether antibodies
Figure 2. PfCelTOS induces a strong humoral immune response in inbred and outbred mice. Sere were collected three weeks after the
first and second immunization (post-1, post-2) and two days prior to challenge (post-3). Antibody kinetics for Balb/c mice (Panel A) and CD-1 mice
(Panel B) were determined using a quantitative ELISA. Data are expressed as the mean mg/ml, error bars represent the SEM of n=15 mice/group (i.e.,
10 challenged mice and 5 reagent mice/group).
doi:10.1371/journal.pone.0012294.g002
Figure 3. PfCelTOS specific antibody concentration does not predict protective status of mice. Data of pre-challenge sera from all tested
dose groups were stratified by protective status of the animals. Box plot indicates the median and the boundaries indicate the 25
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to invade hepatocytes in vitro. Antibodies from mice immunized with
CelTOS adjuvanted with Montanide ISA-720 inhibited invasion in
a dose-dependent manner while sera from mice immunized with
only adjuvant did not inhibit the invasion (Figure 5).
CelTOS-specific antibodies can inhibit the motility of P.
falciparum sporozoites in vitro
It has been reported that live sporozoites deposit a trail of CSP
on glass [10]. As sporozoite motility is an indirect measure of the
viability and health of the parasites, we chose the motility assay as
a functional readout to determine whether antibodies to CelTOS
could inhibit the motility of sporozoites and thus could provide an
explanation for how invasion inhibition was mediated. To this
end, mature P. falciparum sporozoites (day 18–20) from salivary
gland dissection were incubated for 15 min with either control
serum or PfCelTOS-specific antisera or an anti-PfCSP specific
monoclonal antibody (clone 216.5G10) (Figure S2). After the pre-
incubation, the sporozoites were plated without washing onto glass
slides and incubated for 1 hr at 37uC. Incubation of sporozoites
with control mouse serum (either pre-immune or serum from
adjuvant alone injected mice) resulted in the deposition of CSP
trails on slides thus establishing the overall fitness of the sporozoites
(Panel A). Similarly, incubation of sporozoites with CSP-specific
mAbs resulted in extensive trails that often were more pronounced
and stronger than the ones found in the control slides (Panel B)
[11,12]. In contrast, the incubation of sporozoites with anti-
PfCelTOS specific antisera led to either reduced trails or no trails
at all (Panel C). A quantitative analysis of the number of trails
observed in the presence or absence of PfCelTOS-specific antisera
is shown in Table 1 demonstrating that CelTOS antibodies have
the ability to interact with and/or interfere with the apparent
motility of sporozoites. In two of the three experiments we
observed an 85% reduction in the total number of trails (p=0.009
two sample T-test comparing number of trails in control vs.
number of trails in the CelTOS group). Moreover, when testing
the PfCelTOS-specific antibodies and their effect on heterologous
P. berghei sporozoites, we observed a similar reduction in total
number of trails and motility of sporozoites (data not shown).
Immunization with PfCelTOS adjuvanted in Montanide
ISA 720 induces IFN-c as well as IL-4 producing T cells
reactive to homologous and heterologous protein
As no immune correlate has been established for this malaria
vaccine, we sought to characterize the humoral and the cellular
immune response. To this end, the frequencies of CelTOS-specific
IFN-c or IL-4 producing T cells in spleens from inbred Balb/c and
outbred CD-1 mice were measured using an established ELISpot
Figure 4. PfCelTOS-specific antibodies raised by protein immunization react with P. falciparum and P. berghei sporozoites. Reactivity
of polyclonal anti-PfCelTOS antibodies against P. falciparum (Panel A) and P. berghei sporozoites (Panel B) and reactivity of PfCelTOS-specific mAb 2C7
against P. falciparum (Panel C) and P. berghei-specific mAb 15E2 (Panel D) against P. berghei sporozoites. The antisera used for the staining were from
the post-3 sera (= prechallenge) and were tested at 1:200 dilutions. Images were taken at 1,000x magnification.
doi:10.1371/journal.pone.0012294.g004
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in Balb/c mice PfCelTOS-specific splenocytes showed a contem-
poraneous IL-4 and IFN-c response while splenocytes from CD-1
mice produced primarily IFN-c indicating a bias towards Th1.
Secondly, a higher number of PfCelTOS-specific T cells were
induced compared to the higher dose tested in Balb/c. Thirdly,
the cellular responses in CD-1 mice were lower overall compared
to responses in Balb/c mice. Lastly, cross-reactive T cell responses
were observed in both mouse strains when splenocytes were
stimulated with the heterologous antigen, PbCelTOS.
Discussion
CelTOS has been shown to play a pivotal role in the cell
traversal of host cells by malaria parasites [8]. The biological
function for this antigen was described using knockout parasites
that showed a significant reduction in infectivity of cells in both,
the mosquito host as well as the mammalian host [8].
The present study is the first demonstration of the immunolog-
ical impact of an immune response directed against CelTOS. First,
we generated a recombinant PfCelTOS in the E. coli expression
system using the codon harmonized gene sequence from P.
falciparum. The CelTOS protein is highly conserved with 67%
similarity at the amino acid level between the two Plasmodium
species relevant to this analysis, i.e. P. falciparum and P. berghei.
Based on the genetic conservation, celtos may belong to the
category of malaria genes that have evolved in a common ancestor
of Plasmodium parasites. Sequence analysis of 92 blood samples
collected from around the world resulted in 98% homology among
all P. vivax and 91% homology among all isolates tested [13]. The
apparent lack of genetic diversity and antigenic polymorphism
which has commonly thwarted the development paths for specific
malaria vaccine candidates, such as AMA1, MSP1 and MSP2
[14], for example, warrants the further evaluation of CelTOS as a
protective antigen.
The principal finding from this study was the demonstrated
protective efficacy of an anti-PfCelTOS immune response against
sporozoite challenge with a heterologous species, P. berghei a
phenomenon not previously observed with any other malaria
antigen. Using this protein as a vaccine, we conclude that CelTOS
is a protective antigen conferring sterile immunity in a proportion
of both inbred Balb/c and outbred CD-1 mice (Figure 1).
Interestingly, a apparent inverse correlation between immunizing
dose and vaccine efficacy was observed for both mouse strains with
the 10 mg cohorts having the highest vaccine efficacy against the
heterologous challenge. We observed that increasing the dose for
the immunization of CD-1 mice resulted in a reduction of the
protection while the humoral and the cellular responses showed
similar or higher responses at that vaccine dose. It may be that the
higher dose resulted in the loss of high-affinity clones of either B or
T cells which are likely the biologically relevant effectors [15,16].
The apparent efficacy of this vaccine approach may be further
increased by either testing the PfCelTOS in a homologous
challenge model (e.g., either transgenic P. berghei parasites
expressing PfCelTOS) and/or by modifying the adjuvant system
or immunization regimen. Preliminary data suggest that epidermal
Figure 5. CelTOS-specific antibodies inhibit invasion of hepatocytes by P. falciparum sporozoites. Sera from mice immunized either with
CelTOS (and protected against challenge) or adjuvant alone were tested in triplicate for their ability to inhibit hepatocyte infection in vitro. HepG2A16
cells were incubated with sporozoites in the presence or absence of antisera at either 1:100 (black bars) or 1:400 (white bars). Percent inhibition was
calculated based on the number of infected hepatocytes in the control cultures.
doi:10.1371/journal.pone.0012294.g005
Table 1. Quantitative analysis of the effect of anti-PfCelTOS specific antibodies on the motility of P.falciparum sporozoites.
Control serum
a,b PfCelTOS specific serum
b PfCSP specific mAb
c
n spz n trails n spz n trails n spz n trails
Expt 1 46 28 40 8 41 30
Expt 2 130 96 112 9 109 60
Expt 3 62 26 48 3 61 35
aSerum from mice immunized with saline/Montanide ISA 720.
bSerum concentration was 5% (vol/vol) during the 15 min pre-incubation.
cConcentration of mAb 5G10 =50 mg/ml.
doi:10.1371/journal.pone.0012294.t001
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improve vaccine efficacy when the DNA-immunized mice were
challenged with sporozoites (Bergmann-Leitner et al., manuscript
in preparation). These results were surprising as this vaccine
platform was shown to be an effective delivery route for the P.
berghei CSP vaccine developed in our laboratory [17,18,19]. We
are currently evaluating other vaccine platforms and adjuvant
formulations using this antigen.
The analysis of the vaccine-induced immune responses revealed
that both arms of the adaptive immune system are being activated.
The serological response in Balb/c mice was significantly higher
than the CelTOS-specific antibody concentrations measured in
CD-1 mice (Figure 2, 3), but this is not unexpected since inbred
mice will have a more homogenous response and - depending on
the MHC allele - the magnitude of the responses induced may
differ. When analyzing the kinetics of the humoral immune
response induced by PfCelTOS (Figure 2) it became apparent that
two immunizations may suffice to achieve high antibody titers in
Balb/c mice. The serological response in CD-1 mice was lower
compared to the response observed in Balb/c mice and may
indicate genetic restriction where more immunogenic epitopes
bind to H2d.
Stratifying the serological data based on the protective status
failed to identify antibody as the immune correlate of protection
(Figure 3). This does not exclude antibodies for being the mediator
of protection as it may not be the magnitude but rather the quality
(such as affinity) or the fine specificity of the humoral response.
Similar failure in correlating total antibody levels with protection
has been documented for other malaria antigens as well. For
example, evaluating MSP-1p42 as protective antigen in Aotus
monkeys failed to show correlation between total antibody titers
and protection against challenge with bloodstage parasites [20]
and a study employing C3d as molecular adjuvant for the
circumsporozoite protein resulted in high antibody titers, but
reduction in protective efficacy. Further investigation determined
that shifts in the fine specificities of the antibody response that was
not detectable by ELISA using the full length protein was
responsible for the loss of protection [21]. We are currently
exploring in depth the contribution of the various arms of the
immune system in CelTOS-mediated protection.
The antibodies induced by recombinant CelTOS protein were
able to bind to native CelTOS expressed by the sporozoites and
were able to inhibit the invasion of sporozoites into HepG2
hepatoma cells. The most significant finding in this study with
respect to a possible mechanism by which a humoral anti-CelTOS
response would not only inhibit the invasion of sporozoites into
hepatocytes, but also confer protection, came from the in vitro
hepatocyte invasion inhibition assay (ISI) (Figure 5) and the
sporozoite motility assays (Figure S2). Sera from CelTOS-
immunized and protected animals were able to inhibit hepatocyte
invasion in a dose dependent manner, while sera from adjuvant
control mice were not. Furthermore, motility assays were
Figure 6. PfCelTOS specific IFN-c and IL-4 responses show significant cross-reactivity to the heterologous protein. Splenocytes from
Balb/c mice (Panel A, B) and CD-1 mice (Panel C, D) immunized three times with recombinant protein in Montanide ISA 720 were tested in IFN-c
(Panel A,C) and IL-4 (Panel B,D) specific ELISpot assays. Data are expressed as the mean number plus standard error of the mean (SEM) of cytokine
producing cells (spot forming cells, SFC)/10
6 splenocytes of individual mice (n=5/group). Immunization doses for Balb/c =10 mg (high dose), 1 mg
(low dose), immunization dose for CD-1 =25 mg (high dose), 10 mg (low dose). Antigens used for ex vivo stimulation: no antigen (white bar), 10 mg/ml
PfCelTOS (black bar), 10 mg/ml PbCelTOS (hatched bar). For the statistical analysis, vaccinated groups were compared with the Montanide ISA 720
control group stimulated with the same antigen (* indicates p,0.05, two-sided T-test).
doi:10.1371/journal.pone.0012294.g006
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were able to act against sporozoites prior to reaching their final
target. While control mouse antibodies or anti-CSP specific anti-
bodies had no effect on the motility of sporozoites (Figure S2A, B),
anti-CelTOS specific antibodies greatly inhibited their motility
as measured by the deposition of CSP onto the glass slides
(Figure S2C). These results suggest that antibodies targeted to
CelTOS, a secreted protein, impact on sporozoite motility, at least
in vitro, through their ability to inhibit the shedding of CS protein
from the sporozoite. The exact nature of the mechanism by which
these antibodies may impair/abrogate the sporozoites motility
remains to be determined.
The profile of the cellular immune response induced by the
PfCelTOS protein was investigated in both inbred Balb/c mice
and outbred CD-1 mice (Figure 6). Similar to the observation
made for the humoral immune response, we found that the
vaccine induced higher number of CelTOS-specific IFN-c and
IL-4 producing splenocytes in Balb/c than in CD-1 mice.
Moreover, CD-1 mice had only a marginal number of total IL-4
producing cells compared to control Montanide ISA 720
immunized mice. Splenocytes of both mouse strains were also
able to recognize the heterologous CelTOS protein from P. berghei
indicating cross-reactivity at the cellular level.
Taken together, these data suggest that immunization with the
conserved sequence of the CelTOS protein leads to significant
cross-reactivity at both the humoral and cellular level and to
significant cross-protection from a heterologous challenge. While
this is the first such reporting of CelTOS as a protective antigen,
we believe that further optimization by changing either the
regimen and/or adjuvant system or even the vaccine delivery
platform may lead to even higher protective responses, especially
once the antigen can be tested in the appropriate homologous
challenge model.
Although the aim of this study was to assess protective efficacy
against sporozoite challenge, an alternate line of investigation for
CelTOS-specific antibodies based on the natural role of the
CelTOS antigen in cell traversal by ookinetes in addition to that of
sporozoites, is at the sexual blood-stage development within the
mosquito host. We are currently evaluating the transmission
blocking capability of CelTOS-specific antibodies to act against
ookinetes. The mode of action of these CelTOS-specific antibodies
would be through binding on ookinetes and blocking their
traversal through the midgut and thus abrogating further
development to oocysts in the basal lamina. Although highly
speculative, if antibodies to CelTOS were to have such long
ranging activities against both the mammalian and mosquito hosts,
significant strides toward malaria eradication could be envisioned.
This study represents the first such demonstration of protective
efficacy and induction of anti-CelTOS antibodies functional
against the sporozoite stage of the P. falciparum. These results are
encouraging and support further investigations into CelTOS-
based vaccine approaches and the immune mechanisms leading to
the observed protective effect.
Materials and Methods
Ethics Statement
The HepG2, human cell line, is commercially available through
the ATCC. HepG2-A16 is a designated subclone from these cells.
The study was conducted under the approved protocol, IM-04–
08. ‘‘Research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals and adheres to
principles stated in the Guide for the Care and Use of Laboratory
Animals, NRC Publication, 1996 edition. All procedures were
reviewed and approved by the Institute’s Animal Care and Use
Committee, and performed in a facility accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care, International.’’
Malaria Antigens
A 522 bp DNA fragment of PfCelTOS 3D7 (Genbank
Accession number AB194052) was designed by using the codon-
harmonization algorithm [9]. The sequence was synthesized and
provided in the PCR Blunt 3.5 kb vector (Retrogen, San Diego,
CA). The PfCelTOS insert was subcloned into a modified
pET(K2) expression vector (Novagen, Madison, WI), via a 59
BamHI and a 39 NotI site, creating the pET(K2)PfCelTOS (3D7)
plasmid. The resulting plasmid expressed PfCelTOS with an N-
terminal six-histidine tag comprised within a 16 amino acid linker.




2) gal dcm met (DE3)) E. coli using phytone-
based superbroth media containing 40 mg/ml kanamycin and
1.0% glucose. Protein was purified to homogeneity using two
chromatographic steps; Ni
+2-NTA Superflow (Qiagen) followed by
Q anion exchanger (GE) (Fig.S1). The recombinant P. berghei
CelTOS (PbCelTOS) used for stimulation of cellular responses




2) gal dcm (DE3)) similar to PfCelTOS.
PbCelTOS was purified to homogeneity using a two chromato-
graphic step process; Ni
+2-NTA Sepharose and Q anion
exchanger. E. coli host cell protein contaminants (Cygnus
Technology, E. coli HCP ELISA Kit) and residual endotoxin
levels (Cape Cod Associates Pyrochrome LAL assay) were
quantified for each antigen and found to be below the limits of
detection.
Immunizations
Mice used for immunizations were 6- to 8-week-old Balb/c-J
(Jackson Laboratories, Bar Harbor ME) or CD-1 mice females
from Charles River Laboratories (Wilmington MA). Mice were
immunized subcutaneously in the scruff of the neck three times
with 25 or 10 or 1 mg/dose of recombinant PfCelTOS or saline
emulsified in Montanide ISA 720 (Seppic Fairfield NJ) [22].
Challenge
Fourteen days after the final immunization, mice were
challenged by subcutaneous inoculation (into the inguinal region)
with 4,000 P. berghei sporozoites for Balb/c and 15,000 P. berghei
sporozoites for CD-1 mice, dissected from infected mosquito
salivary glands as described elsewhere [23]. The challenge dose
was determined by titration studies in each mouse strain and
compared to the different challenge routes [24]. Infection was
determined by the presence of blood stage parasites in Giemsa
stained thin blood smears on day 6 and day 8 after challenge [21].
Animals that were not infected at that time were tested again on
day 14. Mice that remained un-infected by day 14 were classified
as sterilely protected. We used this evaluation schedule because
animals that are infected with P. berghei ANKA strain malaria
parasites do not self-cure.
ELISA
The ELISA was performed as previously described [21]. Briefly,
96-well plates (Immunolon 2 HB, Thermo Milford, MA) were
coated by overnight incubation with recombinant PfCelTOS at a
concentration of 0.5 mg/ml in PBS (100 ml/well) at 4uC. Plates
were washed with PBS/0.1% Tween 20 using a 96-well plate
Falciparum CelTOS Vaccine
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Sunnyvale, CA) and blocked with blocking buffer (PBS, 1% BSA,
pH 7.5) for 1 hr at 37uC. Sera were serially diluted in blocking
buffer, incubated for 2 h at 37uC, and then washed. Alkaline
phosphatase-conjugated goat anti-mouse IgG (Southern Biotech-
nology, Birmingham, AL) detection antibody was added in
blocking buffer (1:1,000) and incubated for 1 hr at RT. The assay
was developed with BluePhos substrate (Kirkegaard Perry,
Gaithersburg, MD) for 15 min at room temperature, then stopped
with stopping solution (Kirkegaard Perry) and read at 570 nm
(SpectraMax Plus
384, Molecular Devices). Antibody concentration
was determined by establishing a standard curve (run in parallel
with each assay) with purified mouse IgG. For each serum tested,
we determined a concentration that was within the linear portion
of the reaction curve and used this dilution to extrapolate the
actual antibody concentration in the assay wells.
Immunofluorescence assay (IFA)
P. falciparum or P. berghei sporozoites were dissected from salivary
glands of day 18 infected mosquitoes, then washed in Ozaki tubes
and purified over DEAE columns as described elsewhere [23].
Eighteen-spot IFA slides (Cell Point, Gaithersburg, MD) were
coated with approx. 4,000 sporozoites per spot, air-dried and then
stored frozen at 230uC until analysis. Slides were thawed, blocked
for 5 min with PBS with 1% BSA and then incubated with sera at
various concentrations diluted in PBS with 1% BSA for 1 hr at
RT. Spots were then washed with PBS and then incubated with
goat-anti-mouse IgG-FITC (1:100 dilution, Southern Biotech) for
45–60 min at RT. The slides were washed and mounted with
Fluoromount mounting medium. All incubations were done in a
humidified chamber followed by detection using fluorescence
microscopy (Olympus BX41, 1,000 X magnification).
Motility assays
IFA slides (Cell Point, Gaithersburg, MD) were pre-coated with
RPMI-1640 (Invitrogen, Carlsbad, CA) containing 3% BSA
(Sigma) for 15 min at 37uC. After removing the media, 10,000
sporozoites/well were added and incubated for 1 hr in a
humidified chamber at 37uC. Slides and the deposited protein
trails were fixed using 4% paraformaldehyde (10 min, RT). Spots
were blocked with PBS containing 10% FBS for 45 min at 37uC
and then incubated with anti-PfCSP mAb (216.5G10 or 8C10 or
2G3, PfCSP specific mAbs were a generous gift from Dr. Ted
Hall, WRAIR) for 45 min at 37uC. Goat-anti-mouse-IgG-FITC
was added (1:100 dilution, Southern Biotech) to visualize the trails.
Finally, slides were cover-slipped using Fluoromount mounting
media and microscopy was performed (Olympus BX41, 1,000 X
magnification). The number of sporozoites and trails per field were
quantified and only trails were counted that were associated with
sporozoites.
Inhibition of Sporozoite Invasion assay (ISI)
A human hepatoma cell line, HepG2-A16, a subclone of
HepG2 (ATCC, Manassas VA), was seeded at 60,000 cells per
well on 8-well Glass LabTek Chamber slides (Thermo Fisher
Scientific, Rochester NY) and allowed to adhere overnight. Sera
were diluted and added to the hepatocytes to a final concentration
of 1:100 and 1:400. P. falciparum CSP-specific mAb 49-1B2 (kindly
provided by Dr. Ted Hall) was used as positive control, sera from
adjuvant only immunized animals and complete media were used
as negative controls. All experiment sera concentrations and
controls were done in triplicate wells; 25,000 salivary gland
sporozoites were added to each well and allowed to incubate for
3 hrs at 37uCi n5 %C O 2. Slides were washed with PBS and fixed
with ice cold methanol for 10 minutes. Then they were washed
with PBS and stained with the CSP-specific monoclonal antibody
49-1B2 (1:10 dilution) as primary antibody. Goat-anti-mouse IgG-
peroxidase (1:200 dilution) (Kirkegaard Perry) was used as
secondary antibody. Slides color was developed using the DAB
Reagent Set (KPL Gaithersburg MD). Cover glasses were
mounted with Permount (Science Company, Denver CO) and
slides were evaluated with phase- contrast light microscopy
(Olympus BX41, 200 X magnification).
ELISpot
Multiscreen plates (Millipore, Bedford MA) were coated with
either anti-IFN-c or anti-IL-4 capturing antibodies according to
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Plates were blocked using culture medium (DMEM containing
10% FBS, Pen/Strep, HEPES, NEAA, sodium pyruvate, 2-
mercaptoethanol). Thawed splenocytes were counted and plated
at 10
7 cells/ml (50 ml/well). Recombinant proteins, either
PbCelTOS or PfCelTOS, at these test concentrations, 30, 10,
3 mg/ml or 1 mg/ml of both anti-CD3 and anti-CD28 (as positive
control) were used to stimulate the cultures. Plates were incubated
for 36 hrs (IFN-c) or 48 hrs (IL-4) and then processed according to
manufacturer’s instructions. Plates were counted using the AID
Autoimmun Diagnostica GmbH ELISpot reader (Strassberg,
Germany) and software.
Monoclonal antibody production
Balb/c mice were immunized three times with 10 mg PfCelTOS
emulsified in Montanide ISA 720 in three-week intervals. A fourth
immunization was given three days prior to the fusion. The
myeloma cell line SP-2 (ATCC Manassas, VA) was used as the
fusion partner. Fusions were performed using 50% PEG1500
(Boehringer Mannheim, Germany) and hybridoma were selected
using HAT media (Invitrogen).
Statistical analysis
The protective effect of vaccination was evaluated using the
Fisher’s exact test comparing differences between the adjuvant
alone control group and vaccine groups. Statistical significance of
the serological data was tested using ANOVA analysis and Student
T-tests (two-sided) employing the Minitab software package V14
(Penn State University, State College, PA).
Supporting Information
Figure S1 Purification profile of recombinant PfCelTOS protein
used for immunization and in vitro stimulations. Panel A Ni
+2-NTA
Sepharose, Lane 1: SeeBlue MW marker, Lane 2: E. coli lysate
load, Lane 3: unbound flow-through, Lane 4: equilibration buffer
wash, Lane 5: wash buffer 1, Lane 6: wash buffer 2, Lane 7: wash
buffer 3, Lane 8: PfCelTOS elution from Ni
+2-NTA resin. Panel B
Q Sepharose, Lane 1: SeeBlue MW marker, Lane 2: Q load, Lane
3: Q flow through, Lane 4: equilibration buffer wash, Lane 5: Q
wash buffer 1, Lane 6: Q wash buffer 2, Lane 7: Q elution. Final
protein yield was 14 mg/g wet cells from this purification process.
Residual host cell protein (HSP) content and endotoxin levels were
determined as 0.4 ng HCP/50 mg dose and ,0.6EU/mL,
respectively, for the final product PfCelTOS.
Found at: doi:10.1371/journal.pone.0012294.s001 (0.24 MB
TIF)
Figure S2 CelTOS-specific antibodies impair motility of P.
falciparum sporozoites. Sporozoites were pre-incubated with either
control serum (Panel A) or a PfCSP-specific monoclonal antibody
Falciparum CelTOS Vaccine
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dilution of 1:200. Images were taken at 1,000x magnification and
are representative of 4 separate experiments.
Found at: doi:10.1371/journal.pone.0012294.s002 (0.41 MB
TIF)
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